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Abstract
Background: Hyaluronic acid capsule plays a key role in Streptococcus pyogenes virulence. Circulation of mucoid or
highly encapsulated strains has been related to rheumatic fever epidemics and invasive disease in several countries.
In 2009, an outbreak of mucoid S. pyogenes isolates was detected in northern Spain. The aim of the study was to
describe clinical and molecular characteristics of mucoid strains causing this outbreak and to compare them with a
sample of non-mucoid S. pyogenes isolates obtained during the same period of time.
Methods: All S. pyogenes isolates with a mucoid colony morphology (n = 132), 10% of non-mucoid (n = 144) and
all invasive S. pyogenes isolates (n = 7) obtained in 2009 were included. Characterization was performed by
T-agglutination, emm typing, pulsed field gel electrophoresis and multilocus sequence typing.
Results: One clone characterized as emm3.1/ST15 comprised 98.5% (n = 130) of all mucoid isolates. Subjects of all
ages were affected. Main clinical manifestations were pharyngitis and scarlet fever, but this clone also caused
invasive disease: two cases of streptococcal toxic shock syndrome, one arthritis, and one celullitis with a fatal
outcome. Mucoid isolates were more prone to cause invasive disease than non-mucoid isolates (p = 0.001).
Conclusions: Although no acute rheumatic fever cases were detected, the most worrisome characteristics of this
clone were the success for causing invasive disease and the merge of two virulent features: the serotype, emm3,
and capsule hyper-production, expressed as a mucoid morphology.
Background
Group A streptococcus (GAS) strains differ widely in
their encapsulation degree, and those with an exuberant
capsule production have a mucoid morphology when are
cultured on blood agar plates. The expression of the cap-
sule has been related to the virulence of the strain since
it was first recognized [1,2]. In the United States tem-
poral association between a high incidence of rheumatic
fever cases and an increased presence of mucoid S. pyo-
genes strains was observed [3]. More concretely, the
rheumatogenic ability has been associated to a limited
number of emm types such as emm1, 3, 5, 6, or 18 which
often were mucoid [1,3] although this pattern is not held
in all parts of the world, like in Hawaii [4]. Furthermore,
these emm types, and particularly emm1 and emm3
types, are the most prevalent emm types found among
specimens causing invasive GAS disease worldwide [5,6].
By performing blood agar cultures for S. pyogenes detec-
tion, phenotypic characteristics like mucoid colony mor-
phology can be recognized. In fact, recently the
advisability of detecting mucoid isolates in clinical prac-
tice has been emphasized in the literature [1].
In 2009, a sudden emergence of encapsulated S. pyo-
genes isolates was observed among clinical samples
received at the microbiology laboratory of Hospital
Donostia, (Gipuzkoa), in Northern Spain, where circula-
tion of mucoid S. pyogenes strains was highly infrequent
in the past. The aim of this work was to describe mole-
cular characteristics of mucoid isolates causing this out-
break and to compare them to a sample of non-mucoid
S. pyogenes isolates obtained in the same period of time.
Methods
Geographical location
The province of Gipuzkoa is situated in the north
of Spain, flanked by France in the north. Hospital
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Donostia, in Gipuzkoa, is the referral hospital for the
province, and attends a population of 405,745 inhabi-
tants of all ages, children included. The microbiology
laboratory receives all throat samples from Primary Care
Centers of the area to investigate the presence of GAS.
Isolate sample and identification
All S. pyogenes isolates with a mucoid colony morpho-
logy (n = 132) detected in 2009 were included in the
study. Also, randomly selected 10% of non-mucoid
S. pyogenes isolates from pharyngeal swabs (n = 144)
and all S. pyogenes isolates from sterile body sites (n = 7)
obtained that year were analyzed. To investigate the pre-
sence of GAS, samples were routinely cultured on blood
agar plates and incubated overnight in an atmosphere
enriched with 5% of CO2 at 37°C. Colonies were identi-
fied as GAS by bacitracin-susceptibility and agglutination
with specific Group-A streptococci antisera (Slidex
Strepto-kit; bioMérieux, Marcy l’Etoile, France).
Isolate characterization
Characterization was performed by T-agglutination,
emm typing, pulsed field gel electrophoresis (PFGE)
and multilocus sequence typing (MLST) as described
elsewhere [7]. T-type was done by agglutination of
trypsin digested bacteria suspensions using commer-
cial poly- and mono-specific T antisera according to
manufacturer ’s instructions (Sevapharma, Prague,
Czech Republic). emm-type was determined by poly-
merase chain reaction-restriction fragment length poli-
morfism (PCR-RFLP) assay. In those isolates were
emm gene did not amplify, specific recommendations
with a lysate preparation for mucoid strains were fol-
lowed (available at: http://www.cdc.gov/ncidod/bio-
tech/strep/protocol_emm-type.htm). The emm-gene of
all invasive isolates, and at least 15% of each different
emm-type of non-invasive (mucoid and non-mucoid)
isolates were sequenced according to the guidelines of
the Division of Bacterial and Mycotic Diseases, Cen-
ters for Disease Control and Prevention (CDC) (avail-
able at: http://www.cdc.gov/ncidod/biotech/strep/M-
ProteinGene_typing.htm). All mucoid isolates (n =
132) and all non-mucoid emm3 (n = 24) isolates were
investigated by PFGE. Samples were digested with
SmaI enzyme, and results were analyzed by the Diver-
sity Database fingerprinting software, version 2
(BioRad, USA) to construct a dendrogram by the
unweighted pair group method with arithmetic
averages, Dice coefficient, and a position tolerance of
1%. Isolates belonging to the same PFGE pattern had
a similarity higher than 85%. A sample representing at
least 10% of each PFGE pattern (n = 18 isolates) was
characterized by MLST (available at: http://spyogenes.
mlst.net/misc/info.asp).
Antibiotic susceptibility testing
Erythromycin, clindamycin, tetracycline and levofloxacin
susceptibility testing was performed by broth microdilu-
tion method, using Sensititre microtitre trays (Trek
Diagnostic Systems, East Sussex, UK) with Mueller-Hin-
ton II broth (BioMerieux, Mercy l’Etoile, France) supple-
mented with lysed horse blood (3-5% vol/vol). Minimum
inhibitory concentrations (MICs) were performed and
interpreted according to the criteria recommended
by the Clinical and Laboratory Standards Institute
(CLSI) [8].
Statistical analysis
Data were analyzed with the Instat3 program. Chi
square and Fisher’s exact probability tests were used to
perform comparisons.
Ethics Statement
In the present study no human experimentation was
conducted, with all studies carried out on microorgan-
isms. The study and publication of their results was
approved by the ‘Comité Ético de Investigación Clínica
del Área Sanitaria de Gipuzkoa’.
Results and Discussion
In 2009, 1571 S. pyogenes isolates were detected among
samples received at the microbiology laboratory of Hos-
pital Donostia. Of them, 132 were mucoid, representing
the 8.4% of all isolates of that year, while in the previous
four years only 9 mucoid isolates were detected. Circula-
tion of mucoid isolates through 2009 is represented in
figure 1.
Crater et al. [9] demonstrated that capsule production
is greatest in the early logarithmic growth phase in
broth cultures and that its expression is lost when the
stationary growth phase is reached. In our experience,
mucoid colonies showed a wet and glossy shape in
blood agar plates (figure 2), although few of them were
already dried showing a colapsed, rough and “matte”
morphology different to that found in non-mucoid colo-
nies. Incubation of blood agar plates in an atmosphere
enriched with 5% of CO2 enhanced capsule expression.
All mucoid isolates were susceptible to erythromycin,
clindamycin, tetracycline and levofloxacin antimicrobials
showing the following MICs: erythromycin MIC < 0.5
μg/mL; clindamycin MIC < 0.5 μg/mL; tetracycline MIC
< 4 μg/mL; and levofloxacin MIC < 2 μg/mL.
Overall, 98.5% of all mucoid isolates (130/132)
belonged to the emm3.1 type. The two isolates with a
different emm type were characterized as emm5.46 and
emm1.0. In a high percentage of mucoid isolates the
emm gene was difficult to amplify. Probably the vast
amount of hyaluronic acid could have interfered
in DNA extraction as after following specific CDC
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recommendations for mucoid strains, a complete emm
gene amplification success was obtained. PFGE revealed
4 different patterns: patterns A and B, with a similarity
of 73% between them for emm3 mucoid isolates (figure
3), pattern C for the emm1 isolate and pattern D for the
emm5 isolate. All emm3 mucoid isolates, independently
of the PFGE pattern, belonged to the ST15, the emm1
isolate to the ST28 and the emm5 isolate to the ST99.
All emm3 isolates were non T-typeable. This finding
was unrelated to the mucoid capsule because among 89
non-mucoid emm3 isolates obtained in the last 4 years,
only 1 could be T-typed as T3 (data not shown). The
circulation of a mucoid S. pyogenes clone (emm3.1/
ST15) in 2009 contrasts with the results obtained in the
past, when only a few mucoid isolates representing a
varied sample of emm and sequence types were detected
in the community.
Twenty four out of 144 non-mucoid isolates analyzed
in 2009, belonged to the emm3 type, which shared the
same molecular and susceptibility characteristics
(emm3.1/ST15) as the emm3 mucoid isolates, although
belonged only to the PFGE pattern A. The remaining
120 non-emm3 non-mucoid isolates showed percentages
of non-susceptibility in variable proportions (19.2% to
erythromycin, 5.8% to clindamycin, 5.8% to tetracycline
and 1.7% to levofloxacin). The only difference between
emm3 non-mucoid and mucoid isolates was the degree
of hyaluronate encapsulation.
Figure 1 Circulation of mucoid and non-mucoid S. pyogenes isolates in 2009 (n = 1571).
Figure 2 Mucoid S. pyogenes colonies on blood agar plates
after overnight incubation under an atmosphere enriched with
5% CO2.
Figure 3 PFGE patterns found among emm3/ST15 mucoid
S. pyogenes isolates: lanes1, 3, 7, 8 and 11 represent pattern A;
lanes 2, 4-6, 9 and 10 represent pattern B; lane M, lambda
ladder.
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Among mucoid isolates, 87.9% (n = 116) were
obtained from throat samples. Age distribution of
patients affected by the mucoid clone was similar to
that among patients infected by non-mucoid S. pyogenes
isolates: 84.1% (n = 111) and 80.2% (n = 1154) were
children under 14 years old respectively (p = 0.30). The
main clinical manifestations were pharyngitis (n = 55),
scarlet fever (n = 30) and otitis (n = 13), similar to
those found among non-mucoid isolates (n = 1439),
although they also caused 4 cases of invasive disease.
The emm3 type has been ranked among the most preva-
lent emm-types isolated from patients with severe dis-
ease worldwide and has been related to high case
fatality rates [5,6]. In this study four emm3 mucoid iso-
lates were obtained from sterile body sites (3 from
blood and 1 from pleural fluid), two of them associated
with streptococcal toxic shock syndrome, 1 with arthri-
tis, and 1 with celullitis with a fatal outcome. Among
non-mucoid isolates (n = 1439), only 3 cases of invasive
disease were registered (one emm3.1, one emm75, and
one emm87). These data revealed that invasive disease
was more often caused due to mucoid isolates (3%)
compared to non-mucoid isolates (0.21%, p = 0.001) in
2009 in our hospital. Independently of the mucoid fea-
ture, the emm3 type was detected in 71.4% of all inva-
sive GAS disease of that year.
We have found few reports investigating mucoid S.
pyogenes colony phenotype in Spain. Bosch et al. [10]
reported 11 out of 31 invasive S. pyogenes isolates
obtained between 1995 and 1998 showing a mucoid
appearance, although only three were heavily mucoid.
Sierra et al. [11] investigated the presence of mucoid
isolates among invasive GAS infections in injecting
drug users in Barcelona, finding that all isolates were
non-mucoid. By contrast, in other parts of the world,
like in the United States, mucoid GAS circulation has
been more frequently reported. Veasy et al. [3] found
an association between mucoid strains circulation and
an increase of acute rheumathic fever incidence. Rheu-
matic fever is considered a rare disease in Europe [12]
and no cases were produced in our region in the last
ten years. Nevertheless, after the characterization of
this clone which merges a traditionally virulent sero-
type (emm3) and the mucoid feature, pediatricians and
other physicians were alerted in order to prevent the
re-emergence of rheumatic fever into an area pre-
viously free of this disease. We have investigated the
epidemiology of S. pyogenes in our community since
the 90’s, and to our knowledge emm3 S. pyogenes iso-
lates circulate every year but without showing a
mucoid appearance (data not shown). Why these
emm3 S. pyogenes isolates express the mucoid pheno-
type is under research.
Conclusions
To our knowledge, this is the first outbreak of mucoid
S. pyogenes isolates described in the community in
southern Europe, and reminds us of the importance of
performing a comprehensive phenotypic and genotypic
characterization of circulating strains. It is of special
concern that the same isolate merged two important
virulence factors: the emm-type, emm3, and the hiper-
production of capsule observed as a mucoid morpho-
logy, which could have enhanced the ability to cause
severe disease.
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